Insights in Chloroquine Action: Perspectives and Implications in Malaria andCOVID-19

Autor(es)

Pillat, Micheli Mainardi ^[1] ; Kruger, Arne ^[2] ; Ferreira Guimaraes, Lara Mendes ^[3] ; Lameu, Claudiana ^[3] ; de Souza, Edmarcia Elisa ^[2] ; Wrenger, Carsten ^[2] ; Ulrich, Henning ^[3]

Afiliação do(s) autor(es)

^[1] Univ Fed Santa Maria, Hlth Sci Ctr, Dept Microbiol & Parasitol, Santa Maria, RS - Brazil

^[2] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Inst Chem, Dept Biochem, Av Prof Lineu Prestes 748, BR-05508900 Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Cytometry Part A; v. 97, n. 9 AUG 2020.
• Citações Web of Science: 0

Resumo

Malaria is a threat to human mankind and kills about half a million people every year. On the other hand, COVID-19 resulted in several hundred thousand deaths since December 2019 and remains without an efficient and safe treatment. The antimalarials chloroquine (CQ) and its analog, hydroxychloroquine (HCQ), have been tested for COVID-19 treatment, and several conflicting evidence has been obtained. Therefore, the aim of this review was to summarize the evidence regarding action mechanisms of these compounds againstPlasmodiumand SARS-CoV-2 infection, together with cytometry applications. CQ and HCQ act on the renin angiotensin system, with possible implications on the cardiorespiratory system. In this context, flow and image cytometry emerge as powerful technologies to investigate the mechanism of therapeutic candidates, as well as for the identification of the immune response and prognostics of disease severity. Data from the large randomized trials support the conclusion that CQ and HCQ do not provide any clinical improvements in disease severity and progression of SARS-CoV-2 patients, as well as they do not present any solid evidence of increased serious side effects. These drugs are safe and effective antimalarials agents, but in SARS-CoV-2 patients, they need further studies in the context of clinical trials. (c) 2020 International Society for Advancement of Cytometry (AU)

• Processo FAPESP: 18/08820-0 - Inibidores da via de síntese de vitamina B6 entregues por associação com nanopartículas contra Plasmodium sp
• Beneficiário: Arne Kruger
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 15/26722-8 - Drug discovery contra doenças infecciosas humanos
• Beneficiário: Carsten Wrenger
• Linha de fomento: Auxílio à Pesquisa - Temático
• Processo FAPESP: 18/07366-4 - Receptores de purinas e cininas como alvos de estudo e intervenção terapêutica em doenças neurológicas
• Beneficiário: Alexander Henning Ulrich
• Linha de fomento: Auxílio à Pesquisa - Temático
• Processo FAPESP: 15/19128-2 - Mecanismos de metástase de tumores infantis para a medula óssea
• Beneficiário: Claudiana Lameu
• Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores